共 230 条
[1]
Siegel RL(2015)Cancer statistics, 2015 CA Cancer J Clin 65 5-29
[2]
Miller KD(2006)Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726-3734
[3]
Jemal A(2011)Gene expression profile testing for breast cancer and the use of chemotherapy, serious adverse effects, and costs of care Breast Cancer Res Treat 130 619-626
[4]
Paik S(2007)American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287-5312
[5]
Tang G(2007)Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies Cancer 109 1011-1018
[6]
Shak S(2010)Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20 J Clin Oncol 28 1677-1683
[7]
Kim C(2016)NCCN Clinical Practice Guidelines in Oncology J Natl Compr Cancer Netw 14 324-354
[8]
Baker J(2001)Socioeconomic status and breast cancer incidence in California for different race/ethnic groups Cancer Causes Control 12 703-711
[9]
Kim W(2004)A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 2817-2826
[10]
Cronin M(2012)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 379 432-444